| scholarly article | Q13442814 |
| P50 | author | Jeanne M. Schilder | Q93819022 |
| Daniela E. Matei | Q79322621 | ||
| P2093 | author name string | Cynthia S Johnson | |
| Lee Ann Baldridge | |||
| Gregory Sutton | |||
| John McClean | |||
| Tim Breen | |||
| Robert E Emerson | |||
| Nancy Menning | |||
| Charles Whalen | |||
| Doyle Stephens | |||
| P2860 | cites work | Gene expression signature with independent prognostic significance in epithelial ovarian cancer | Q80908361 |
| RETRACTED: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class | Q34308033 | ||
| Effect of platelet-derived growth factor receptor-beta inhibition with STI571 on radioimmunotherapy. | Q34343317 | ||
| Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. | Q34866669 | ||
| Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials | Q35125943 | ||
| Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer | Q35791273 | ||
| Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts | Q36611170 | ||
| Expression and localisation of Akt-1, Akt-2 and Akt-3 correlate with clinical outcome of prostate cancer patients | Q36614450 | ||
| Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma | Q36695240 | ||
| Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). | Q38506719 | ||
| Both platelet-derived growth factor receptor (PDGFR)-alpha and PDGFR-beta promote murine fibroblast cell migration | Q38524742 | ||
| PDGF BB induces VEGF secretion in ovarian cancer. | Q40036458 | ||
| Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer. | Q40343201 | ||
| Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume. | Q40477780 | ||
| Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum | Q40543982 | ||
| Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation | Q40593443 | ||
| PDGF alpha- and beta-receptors activate unique and common signal transduction pathways | Q41516226 | ||
| Transforming protein of simian sarcoma virus stimulates autocrine growth of SSV-transformed cells through PDGF cell-surface receptors | Q42817650 | ||
| Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan | Q43675453 | ||
| Angiogenesis stimulated by PDGF-CC, a novel member in the PDGF family, involves activation of PDGFR-alphaalpha and -alphabeta receptors | Q44175822 | ||
| A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study | Q44315213 | ||
| Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium | Q44544392 | ||
| Weekly docetaxel for patients with platinum/paclitaxel/irinotecan-resistant relapsed ovarian cancer: a phase I study | Q44685487 | ||
| Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer | Q45018087 | ||
| KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors | Q45151889 | ||
| A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. | Q45158856 | ||
| Gene expression in epithelial ovarian carcinoma | Q46405024 | ||
| Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers | Q46405029 | ||
| Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. | Q46791717 | ||
| Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. | Q53972578 | ||
| Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma. | Q54044592 | ||
| Are we taking without giving in return? The ethics of research-related biopsies and the benefits of clinical trial participation | Q56786765 | ||
| A prospective analysis of imatinib-induced c-kit modulation in ovarian cancer | Q60673301 | ||
| Two classes of PDGF receptor recognize different isoforms of PDGF | Q69828348 | ||
| Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer | Q71975333 | ||
| Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor | Q72121269 | ||
| Lack of expression of c-KIT in ovarian cancers is associated with poor prognosis | Q73911390 | ||
| Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group | Q78785334 | ||
| Phase II trial of weekly docetaxel for patients with relapsed ovarian cancer who have previously received paclitaxel--ANZGOG 02-01 | Q79322354 | ||
| AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas | Q24294176 | ||
| Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors | Q24676378 | ||
| New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada | Q27860904 | ||
| Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer | Q29616123 | ||
| Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors | Q29618610 | ||
| Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome | Q33336718 | ||
| Cancer statistics, 2000. | Q33895772 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | platinum | Q880 |
| ovarian cancer | Q172341 | ||
| imatinib | Q177094 | ||
| docetaxel | Q420436 | ||
| peritoneal carcinomatosis | Q2071182 | ||
| P304 | page(s) | 723-732 | |
| P577 | publication date | 2008-08-01 | |
| P1433 | published in | Cancer | Q326041 |
| P1476 | title | Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial | |
| P478 | volume | 113 |
| Q36988077 | A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy. |
| Q34433040 | A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer |
| Q45228150 | A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer |
| Q51036417 | A phase II trial of docetaxel and bevacizumab in recurrent ovarian cancer within 12 months of prior platinum-based chemotherapy. |
| Q35205410 | Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches. |
| Q33583598 | Antivascular therapy for epithelial ovarian cancer |
| Q37399899 | Beyond chemotherapy: targeted therapies in ovarian cancer |
| Q38034167 | Cancerous ovarian stem cells: obscure targets for therapy but relevant to chemoresistance. |
| Q36171268 | Clinical utility of targeted treatments in the management of epithelial ovarian cancer |
| Q34975642 | Comparative profiling of N-glycans isolated from serum samples of ovarian cancer patients and analyzed by microchip electrophoresis |
| Q37453118 | Current status on biologic therapies in the treatment of epithelial ovarian cancer |
| Q39843822 | Docetaxel enhances the cytotoxic effects of imatinib on Philadelphia positive human chronic myeloid leukemia cells |
| Q38497958 | Emerging therapies: angiogenesis inhibitors for ovarian cancer |
| Q37776846 | Epithelial ovarian cancer: Focus on targeted therapy |
| Q42265763 | Ginsenoside-Rb1 targets chemotherapy-resistant ovarian cancer stem cells via simultaneous inhibition of Wnt/β-catenin signaling and epithelial-to-mesenchymal transition |
| Q64068457 | Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer |
| Q38323440 | Investigational therapies up to Phase II which target PDGF receptors: potential anti-cancer therapeutics. |
| Q35874750 | N-linked glycan structures and their expressions change in the blood sera of ovarian cancer patients. |
| Q47424260 | Novel antiangiogenic therapies in ovarian cancer |
| Q34233273 | Overcoming platinum resistance in ovarian carcinoma |
| Q37826911 | Overview of anti-angiogenic agents in development for ovarian cancer |
| Q36694926 | Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate |
| Q83566218 | Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube |
| Q60930283 | Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer |
| Q46486238 | Rationale for combination use of targeted agents in ovarian cancer: do we have one? |
| Q54694765 | Rationale for the development of IMC-3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet-derived growth factor receptor alpha. |
| Q91869719 | Review: Mechanotransduction in ovarian cancer: Shearing into the unknown |
| Q36098576 | Structural Characterization of Serum N-Glycans by Methylamidation, Fluorescent Labeling, and Analysis by Microchip Electrophoresis |
| Q34878868 | Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action |
| Q37814085 | Targeting non-malignant disorders with tyrosine kinase inhibitors. |
| Q58789499 | Targeting the Microenvironment in High Grade Serous Ovarian Cancer |
| Q38118388 | Targeting tyrosine-kinases in ovarian cancer |
| Q30248645 | The Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review |
| Q38144166 | The potential of sunitinib as a therapy in ovarian cancer |
| Q98771756 | Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy |
| Q26770477 | Two drugs are better than one. A short history of combined therapy of ovarian cancer |
| Q35584349 | Will imatinib compromise reproductive capacity? |
| Q39314503 | c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling. |
Search more.